Pharmaceutical and medical device manufacturers operate in a highly regulated environment where operational efficiency, data integrity, and regulatory compliance must coexist. Manufacturing Execution Systems (MES) have traditionally served as the backbone of digital manufacturing, enforcing standardized workflows, batch traceability, electronic records, and compliance with regulations such as FDA 21 CFR Part 11, EU Annex 11, and Good Manufacturing Practice (GMP). While MES solutions provide robust governance and audit readiness, they are often associated with long implementation cycles, high costs, and limited flexibility in addressing shop-floor requirements that change quickly.
Low-Code/No-Code (LCNC) platforms have emerged as a complementary enabler of agile application development. Platforms such as Tulip and Mendix allow engineers, quality teams, and business users to design and deploy applications rapidly using visual modeling tools. These platforms support digital work instructions, operator performance monitoring, downtime tracking, and AI-driven defect detection, but face challenges related to scalability, validation, and compliance when deployed independently in regulated settings.
This paper proposes a hybrid framework that strategically integrates LCNC platforms with MES, positioning MES as the system of record for validated, GxP-critical processes and LCNC as a flexible innovation layer for rapid digitization. The framework draws on a qualitative, conceptual research methodology grounded in industry practice, architectural analysis, and regulatory frameworks, and is illustrated through comparative analysis and a proposed reference architecture. Organizations adopting this approach can reduce application backlogs, accelerate digital transformation, and maintain regulatory confidence, with the framework remaining extensible to other regulated manufacturing sectors.